ArticleThe Journal of clinical endocrinology and metabolism2026
Cord Blood DNA Methylation at CHD13 Is Associated with Adiponectin Levels at 10 to 14 Years of Age.
Article in The Journal of clinical endocrinology and metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cord Blood DNA Methylation and Large-for-Gestational-Age Birth: A Pilot Epigenome-Wide Study in the GROW Cohort.Epigenomes · 2026Article
- Circulating spexin and adiponectin as early biomarkers of insulin resistance in pediatric obesity.BMC endocrine disorders · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundLow adiponectin levels are associated with higher insulin resistance, the development of type 2 diabetes, and greater adiposity in adults, but the evidence in youth is limited. This study aimed to assess adiponectin as a biomarker of adverse metabolic health in youth and to examine whether cord blood DNA methylation (cbDNAm) is associated with child adiponectin levels.
methodsParticipants from the Hyperglycemia and Adverse Pregnancy Outcome Study and Follow-up Study were included based on availability of cbDNAm, child anthropometry, child adiponectin levels, and glucose oral glucose tolerance test measures (n = 2265) collected at mean age 11.4 ± 1.2 years. Cross-sectional associations between child log-transformed adiponectin and child adiposity and glycemic measures were evaluated via partial correlation. Linear regression models were used for epigenome-wide analysis of cbDNAm and child adiponectin levels.
resultsAfter adjustment for covariates, lower child adiponectin levels were correlated with higher adiposity/dysglycemia outcomes (sum of skinfolds, r = -0.285 and glucose sum of z-scores, r = -0.070) as well as lower Matsuda (r = 0.135) and disposition (r = 0.062) indices. Linear regression was used to assess associations between cbDNAm and child adiponectin levels with covariate adjustments. cbDNAm at cg02713721, located in the CDH13 locus, was associated with child adiponectin levels (β = .35, Bonferroni-adjusted P = .01).
conclusionThis study provides evidence of adiponectin as a biomarker of adverse metabolic health in youth. The association of methylation in CDH13, a gene involved in glucose regulation, with child adiponectin levels suggests a contribution to programming of future metabolic health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.